Core Viewpoint - The company, He Yu-B (02256), has seen a significant stock price increase following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, Goresan, for treating KRAS G12C mutated NSCLC in China, marking a progression to Phase II clinical trials. Additionally, the company has been included in the MSCI Global Small Cap Index, which is expected to enhance its global funding visibility and liquidity [1]. Group 1 - The stock price of He Yu-B increased by over 6% in early trading, currently up 4.92% at HKD 17.93, with a trading volume of HKD 39.0714 million [1]. - The IND application for the combination treatment of ABSK043 and Goresan has been approved in China, allowing the drug to enter Phase II clinical trials [1]. - The inclusion in the MSCI Global Small Cap Index is anticipated to boost the company's global funding attention and positively impact liquidity [1]. Group 2 - CICC's research report highlights that ABSK043 has the potential to be a globally competitive oral small molecule PD-L1 inhibitor [1]. - The company’s strategy of combining oral therapies is expected to offer better patient compliance and safety profiles compared to the traditional injection plus oral combination [1]. - Future clinical developments of the combination treatment are deemed worthy of attention [1].
港股异动 | 和誉-B(02256)早盘涨超6% ABSK043联用戈来雷塞进入二期临床